Governor Malloy has signed the following bills affecting bioscience in Connecticut:

SB 371 (now PA 16-214) AN ACT CONCERNING THE USE OF EXPERIMENTAL DRUGS. This bill shall take effect October 1, 2016.

This bill allows certain terminally ill patients to access medications and devices not yet approved for general use. The bill allows investigational drug manufacturers to provide eligible patients with investigational drugs.

SB 306 (now PA 16-201) AN ACT CONCERNING THE OFFICE OF THE PERMIT OMBUDSMAN AND ASSISTANCE FOR BIOSCIENCE COMPANIES. This bill shall take effect October 1, 2016.

The bill makes projects to develop bioscience businesses eligible for assistance from the Department of Economic and Community Development’s (DECD) Office of the Permit Ombudsman.

SB 401 (now PA 16-204) AN ACT CONCERNING THE CONNECTICUT BIOSCIENCE INNOVATION FUND AND INVESTMENTS BY CONNECTICUT INNOVATIONS, INCORPORATED. This bill shall take effect July 1, 2016.

This bill allows Connecticut Innovations, Inc. (CI) to use its unrestricted funds and funds in the Connecticut Bioscience Innovation Fund (CBIF) to invest in private equity investment funds under certain conditions.

SB 445 (now SA 16-20) AN ACT ESTABLISHING A HEALTH DATA COLLABORATIVE WORKING GROUP. This bill shall take effect from passage.

This bill directs the chairpersons of the Commission on Economic Competitiveness to appoint and convene a health data collaborative working group to examine and make recommendations.

SB 308 (now SA 16-21) AN ACT CONCERNING DEVELOPMENT OF RECOMMENDATIONS FOR A STRANDED RESEARCH AND DEVELOPMENT TAX CREDIT PROGRAM. This bill shall take effect from passage.

This bill requires the Department of Economic and Community Development (DECD) to develop legislative recommendations regarding the exchange of unused research and development credits for state financial assistance.